Cargando…
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antipsychotics. They are said to have treatment-resistant schizophrenia (TRS). Clozapine is still the only effective treatment for TRS, although it is underused in clinical practice. Initial use is delayed,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106233/ https://www.ncbi.nlm.nih.gov/pubmed/27853387 http://dx.doi.org/10.2147/PGPM.S115741 |